688302 海创药业-U
已收盘 10-30 15:00:00
资讯
新帖
简况
海创药业（688302）2026年三季报简析：增收不增利，存货明显上升
证券之星 · 06:27
海创药业（688302）2026年三季报简析：增收不增利，存货明显上升
海创药业(688302.SH)发布前三季度业绩，归母净亏损1.01亿元
智通财经 · 10-30 21:30
海创药业(688302.SH)发布前三季度业绩，归母净亏损1.01亿元
海创药业(688302)9月30日股东户数0.77万户，较上期增加7.49%
证券之星 · 10-30 19:12
海创药业(688302)9月30日股东户数0.77万户，较上期增加7.49%
海创药业（688302）10月27日主力资金净买入2863.20万元
证券之星 · 10-28
海创药业（688302）10月27日主力资金净买入2863.20万元
海创药业（688302）10月20日主力资金净卖出106.00万元
证券之星 · 10-21
海创药业（688302）10月20日主力资金净卖出106.00万元
海创药业（688302）10月13日主力资金净卖出94.66万元
证券之星 · 10-14
海创药业（688302）10月13日主力资金净卖出94.66万元
海创药业（688302）披露HP515片IIa期临床试验数据被AASLD年会接受为最新突破摘要，10月09日股价上涨1.65%
证券之星 · 10-09
海创药业（688302）披露HP515片IIa期临床试验数据被AASLD年会接受为最新突破摘要，10月09日股价上涨1.65%
海创药业（688302）10月8日主力资金净买入124.29万元
证券之星 · 10-09
海创药业（688302）10月8日主力资金净买入124.29万元
每周股票复盘：海创药业（688302）完成董事会换届及核心技术人员调整
证券之星 · 09-13
每周股票复盘：海创药业（688302）完成董事会换届及核心技术人员调整
海创药业（688302）披露2026年第一次临时股东会法律意见书，9月11日股价下跌3.42%
证券之星 · 09-11
海创药业（688302）披露2026年第一次临时股东会法律意见书，9月11日股价下跌3.42%
每周股票复盘：海创药业（688302）调整募投项目
证券之星 · 09-06
每周股票复盘：海创药业（688302）调整募投项目
海创药业（688302）披露首次公开发行股票部分募投项目子项目调整公告，9月4日股价下跌2.58%
证券之星 · 09-04
海创药业（688302）披露首次公开发行股票部分募投项目子项目调整公告，9月4日股价下跌2.58%
每周股票复盘：海创药业（688302）股东户数减少10.5%，研发占比104.92%
证券之星 · 08-30
每周股票复盘：海创药业（688302）股东户数减少10.5%，研发占比104.92%
海创药业（688302）披露2026年半年度报告，8月26日股价下跌1.4%
证券之星 · 08-26
海创药业（688302）披露2026年半年度报告，8月26日股价下跌1.4%
每周股票复盘：海创药业（688302）氘恩扎鲁胺启动BCR前列腺癌Ⅲ期临床
证券之星 · 07-19
每周股票复盘：海创药业（688302）氘恩扎鲁胺启动BCR前列腺癌Ⅲ期临床
海创药业：氘恩扎鲁胺软胶囊临床试验获批准
证券之星 · 07-15
海创药业：氘恩扎鲁胺软胶囊临床试验获批准
每周股票复盘：海创药业（688302）核心产品上市并进医保，公司调整研发策略
证券之星 · 06-28
每周股票复盘：海创药业（688302）核心产品上市并进医保，公司调整研发策略
海创药业（688302）披露关于2025年年度报告信息披露监管问询函的专项核查意见，6月26日股价下跌5.22%
证券之星 · 06-26
海创药业（688302）披露关于2025年年度报告信息披露监管问询函的专项核查意见，6月26日股价下跌5.22%
每周股票复盘：海创药业（688302）HP515临床试验达主要终点
证券之星 · 06-20
每周股票复盘：海创药业（688302）HP515临床试验达主要终点
海创药业（688302）披露HP515治疗MASH临床IIa期试验最终分析结果，6月16日股价上涨3.89%
证券之星 · 06-16
海创药业（688302）披露HP515治疗MASH临床IIa期试验最终分析结果，6月16日股价上涨3.89%
加载更多
公司概况
公司名称：
海创药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-04-12
主营业务：
海创药业股份有限公司的主营业务是药品的研发、生产、销售以及技术咨询、技术转让。公司的主要产品是海纳安、HP518、HP537、HP515、GLP小分子、HP570、HC-X049。
发行价格：
42.92
{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业-U","latestPrice":30.46,"timestamp":1793343600000,"preClose":30.46,"halted":0,"volume":3944211,"delay":0,"changeRate":0,"floatShares":99015600,"shares":99015600,"eps":-1.4001,"marketStatus":"已收盘","change":0,"latestTime":"10-30 15:00:00","open":30.15,"high":32.23,"low":29.22,"amount":121000000,"amplitude":0.0988,"askPrice":30.48,"askSize":137,"bidPrice":30.46,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-1.4001,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":30.46,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":33.51,"lowLimit":27.41,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":99015598,"isCdr":false,"pbRate":2.99,"roa":"--","roe":"--","epsLYR":-1.39,"committee":0.289538,"marketValue":3016000000,"turnoverRate":0.0398,"status":2,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-02。","afterMarket":{"amount":6092,"volume":200,"close":30.46,"buyVolume":0,"sellVolume":1600,"time":1793345637746,"indexStatus":"已收盘 10-30 15:30:00","preClose":30.46},"floatMarketCap":3016000000},"requestUrl":"/m/hq/s/688302/","defaultTab":"news","newsList":[{"id":"2680827236","title":"海创药业（688302）2026年三季报简析：增收不增利，存货明显上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2680827236","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680827236?lang=zh_cn&edition=full","pubTime":"2026-11-01 06:27","pubTimestamp":1793485662,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期海创药业发布2026年三季报。截至本报告期末，公司营业总收入8572.77万元，同比上升267.11%，归母净利润-1.01亿元，同比下降1.39%。本报告期海创药业存货明显上升，存货同比增幅达1461.46%。持有海创药业最多的基金为益民核心增长混合，目前规模为0.26亿元，最新净值1.495，较上一交易日下跌1.58%，近一年上涨1.91%。本文数据来源于海创药业2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110100001493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679217617","title":"海创药业(688302.SH)发布前三季度业绩，归母净亏损1.01亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679217617","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679217617?lang=zh_cn&edition=full","pubTime":"2026-10-30 21:30","pubTimestamp":1793367022,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业(688302.SH)发布2026年第三季度报告，公司前三季度实现营业收入8572.77万元，同比增长267.11%;归属于上市公司股东的净亏损1.01亿元;归属于上市公司股东的扣除非经常性损益的净亏损1.14亿元;基本每股收益-1.02元。前三季度，公司营业收入同比增长主要系公司首个1类新药海纳安®于2025年12月纳入国家医保药品目录(2026年1月1日正式执行)，本年药品销售收入增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679218777","title":"海创药业(688302)9月30日股东户数0.77万户，较上期增加7.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679218777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679218777?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:12","pubTimestamp":1793358734,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海创药业披露，截至2026年9月30日公司股东户数为7681.0户，较6月30日增加535.0户，增幅为7.49%。在化学制药行业个股中，海创药业股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.98万户。从股价来看，2026年6月30日至2026年9月30日，海创药业区间跌幅为5.2%，在此期间股东户数增加535.0户，增幅为7.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678805884","title":"海创药业（688302）10月27日主力资金净买入2863.20万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678805884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678805884?lang=zh_cn&edition=full","pubTime":"2026-10-28 08:30","pubTimestamp":1793147444,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月27日收盘，海创药业报收于28.85元，上涨1.94%，换手率4.55%，成交量4.51万手，成交额1.33亿元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入959.63万元，融资偿还769.66万元，融资净买入189.96万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800013880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677014610","title":"海创药业（688302）10月20日主力资金净卖出106.00万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677014610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677014610?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:24","pubTimestamp":1792542292,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月20日收盘，海创药业报收于29.1元，上涨3.89%，换手率1.23%，成交量1.22万手，成交额3491.92万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入213.16万元，融资偿还254.56万元，融资净偿还41.4万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100007076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675893396","title":"海创药业（688302）10月13日主力资金净卖出94.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675893396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675893396?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:31","pubTimestamp":1791937907,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，海创药业报收于30.19元，下跌2.01%，换手率1.22%，成交量1.21万手，成交额3630.38万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入494.3万元，融资偿还326.18万元，融资净买入168.12万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674853438","title":"海创药业（688302）披露HP515片IIa期临床试验数据被AASLD年会接受为最新突破摘要，10月09日股价上涨1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674853438","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674853438?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:16","pubTimestamp":1791540996,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，海创药业报收于32.09元，较前一交易日上涨1.65%，最新总市值为31.77亿元。该股当日开盘31.6元，最高32.2元，最低30.55元，成交额达4117.04万元，换手率为1.33%。海创药业于近日披露《自愿披露关于HP515片IIa期临床试验数据被美国肝病研究协会接受为年会最新突破摘要的公告》。此前I期研究已入选2026年欧洲肝病年会。目前HP515片尚未上市，后续临床进展及审批存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900030394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674188965","title":"海创药业（688302）10月8日主力资金净买入124.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674188965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674188965?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:33","pubTimestamp":1791506031,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，海创药业报收于31.57元，下跌5.31%，换手率1.73%，成交量1.71万手，成交额5496.91万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入310.32万元，融资偿还276.29万元，融资净买入34.03万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667647500","title":"每周股票复盘：海创药业（688302）完成董事会换届及核心技术人员调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2667647500","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667647500?lang=zh_cn&edition=full","pubTime":"2026-09-13 03:25","pubTimestamp":1789241111,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，海创药业报收于29.13元，较上周的31.38元下跌7.17%。本周，海创药业9月7日盘中最高价报31.66元。本周关注点公司公告汇总：海创药业完成第三届董事会换届选举，YUANWEI CHEN（陈元伟）当选董事长及总经理。海创药业于2026年9月11日召开第三届董事会第一次会议，聘任刘杰先生为公司董事会秘书。刘杰先生已取得深交所董秘资格，尚未取得上交所科创板董秘培训合格证明，待完成培训并备案后正式履职，任期至第三届董事会届满。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300001049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666785565","title":"海创药业（688302）披露2026年第一次临时股东会法律意见书，9月11日股价下跌3.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666785565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666785565?lang=zh_cn&edition=full","pubTime":"2026-09-11 22:30","pubTimestamp":1789137016,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，海创药业报收于29.13元，较前一交易日下跌3.42%，最新总市值为28.84亿元。近日，北京通商（成都）律师事务所出具《关于海创药业股份有限公司2026年第一次临时股东会的法律意见书》。公告显示，海创药业2026年第一次临时股东会于2026年9月11日以现场与网络投票方式召开，审议通过了关于调整首次公开发行股票部分募投项目子项目的议案，并选举产生了第三届董事会非独立董事和独立董事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100050586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665665163","title":"每周股票复盘：海创药业（688302）调整募投项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2665665163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665665163?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:23","pubTimestamp":1788636190,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，海创药业报收于31.38元，较上周的33.82元下跌7.21%。本周，海创药业9月1日盘中最高价报34.45元。9月4日盘中最低价报31.21元，股价触及近一年最低点。海创药业当前最新总市值31.07亿元，在化学制药板块市值排名127/149，在两市A股市值排名4312/5214。本周关注点公司公告汇总：海创药业拟调整部分募投项目，新增HP570子项目，延期HP518至2027年底，暂停HP537投入。同时，公司拟选举第三届董事会非独立董事及独立董事候选人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664433307","title":"海创药业（688302）披露首次公开发行股票部分募投项目子项目调整公告，9月4日股价下跌2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664433307","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664433307?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:41","pubTimestamp":1788514896,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，海创药业报收于31.38元，较前一交易日下跌2.58%，最新总市值为31.07亿元。该股当日开盘32.2元，最高32.84元，最低31.21元，成交额达6485.6万元，换手率为2.04%。公司于近日披露《2026年第一次临时股东会会议资料》公告。公告显示，海创药业拟对首次公开发行股票部分募投项目子项目进行调整：新增HP570子项目，延期HP518子项目实施期限至2027年12月31日，暂停HP537子项目后续募集资金投入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400031729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663155043","title":"每周股票复盘：海创药业（688302）股东户数减少10.5%，研发占比104.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663155043","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663155043?lang=zh_cn&edition=full","pubTime":"2026-08-30 07:59","pubTimestamp":1788047947,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，海创药业报收于33.82元，较上周的36.47元下跌7.27%。本周，海创药业8月24日盘中最高价报36.77元。负债率20.86%，毛利率97.34%，研发投入占营业收入比例为104.92%。公司披露募集资金专项报告，截至2026年6月30日累计使用募集资金897,253,575.40元，账户余额12,768,330.19元，1.1亿元用于现金管理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662710641","title":"海创药业（688302）披露2026年半年度报告，8月26日股价下跌1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662710641","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662710641?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:22","pubTimestamp":1787754153,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘，海创药业报收于34.55元，较前一交易日下跌1.4%，最新总市值为34.21亿元。该股当日开盘35.05元，最高35.8元，最低34.0元，成交额达5256.4万元，换手率为1.53%。近日，海创药业股份有限公司披露《2026年半年度报告》。本报告期实现营业收入54,970,550.02元，同比增长317.48%；归属于上市公司股东的净利润为-56,218,129.78元，上年同期为-61,853,200.96元。研发投入占营业收入的比例为104.92%，较上年同期减少327.73个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600052909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652123011","title":"每周股票复盘：海创药业（688302）氘恩扎鲁胺启动BCR前列腺癌Ⅲ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2652123011","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652123011?lang=zh_cn&edition=full","pubTime":"2026-07-19 02:43","pubTimestamp":1784400187,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，海创药业报收于37.0元，较上周的38.6元下跌4.15%。本周关注点公司公告汇总：氘恩扎鲁胺软胶囊获准开展高风险生化复发前列腺癌Ⅲ期临床试验。该适应症此前国内无获批药物，氘恩扎鲁胺的获批填补了临床空白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651546853","title":"海创药业：氘恩扎鲁胺软胶囊临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651546853","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651546853?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:00","pubTimestamp":1784116848,"startTime":"0","endTime":"0","summary":"海创药业(688302.SH)公告称，公司收到中国国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意氘恩扎鲁胺软胶囊开展前列腺癌Ⅲ期临床实验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500040970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646316680","title":"每周股票复盘：海创药业（688302）核心产品上市并进医保，公司调整研发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2646316680","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646316680?lang=zh_cn&edition=full","pubTime":"2026-06-28 04:14","pubTimestamp":1782591252,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，海创药业报收于33.06元，较上周的35.55元下跌7.0%。公司公告汇总中信证券就海创药业2025年年度报告信息披露监管问询函进行核查并发表意见。公司核心产品氘恩扎鲁胺软胶囊于2025年5月在国内获批上市，用于治疗转移性去势抵抗性前列腺癌，已纳入国家医保目录。海创药业就上交所对公司2025年年度报告的信息披露监管问询函作出回复，内容涉及研发进展、主营收入、建设项目及其他事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646661503","title":"海创药业（688302）披露关于2025年年度报告信息披露监管问询函的专项核查意见，6月26日股价下跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646661503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646661503?lang=zh_cn&edition=full","pubTime":"2026-06-26 23:06","pubTimestamp":1782486380,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，海创药业报收于33.06元，较前一交易日下跌5.22%，最新总市值为32.73亿元。该股当日开盘34.58元，最高34.88元，最低32.66元，成交额达5046.17万元，换手率为1.53%。公告显示，中信证券就海创药业2025年年度报告信息披露监管问询函进行核查并发表意见。2025年公司实现营业收入2,047万元，研发费用11,270.77万元。成都生产基地于2026年1月底通过GMP检查，实现制剂自产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600046246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644652850","title":"每周股票复盘：海创药业（688302）HP515临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2644652850","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644652850?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:09","pubTimestamp":1781896191,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，海创药业报收于35.55元，较上周的34.27元上涨3.74%。本周，海创药业6月18日盘中最高价报35.8元。6月15日盘中最低价报33.14元。海创药业当前最新总市值35.2亿元，在化学制药板块市值排名112/150，在两市A股市值排名4018/5206。药物总体耐受性良好，未发生严重不良事件。公司已完成I期临床试验，HP515已获中美监管部门批准开展MASH适应症临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000001883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759069","title":"海创药业（688302）披露HP515治疗MASH临床IIa期试验最终分析结果，6月16日股价上涨3.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759069","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643759069?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:01","pubTimestamp":1781607671,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，海创药业报收于34.73元，较前一交易日上涨3.89%，最新总市值为34.39亿元。近日，海创药业发布《自愿披露关于治疗代谢相关脂肪性肝炎药物HP515临床IIa期试验取得最终分析结果的公告》。公告显示，公司自主研发的HP515片在治疗代谢相关脂肪性肝炎的IIa期临床试验中达到主要终点和关键次要终点。公司已完成I期临床试验，HP515已获中美监管部门批准开展MASH适应症临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600036845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793534365648,"stockEarnings":[{"period":"1week","weight":0.0621},{"period":"1month","weight":-0.0864},{"period":"3month","weight":-0.0702},{"period":"6month","weight":-0.3077},{"period":"1year","weight":-0.4315},{"period":"ytd","weight":-0.3805}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海创药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7681人(较上一季度增加7.49%)","perCapita":"12890股","listingDate":"2022-04-12","address":"四川省成都市双流区凤凰路558号","registeredCapital":"9901万元","survey":" 海创药业股份有限公司的主营业务是药品的研发、生产、销售以及技术咨询、技术转让。公司的主要产品是海纳安、HP518、HP537、HP515、GLP小分子、HP570、HC-X049。","listedPrice":42.92},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业-U(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业-U(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业-U,688302,海创药业-U股票,海创药业-U股票老虎,海创药业-U股票老虎国际,海创药业-U行情,海创药业-U股票行情,海创药业-U股价,海创药业-U股市,海创药业-U股票价格,海创药业-U股票交易,海创药业-U股票购买,海创药业-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业-U(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业-U(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}